EA201890851A1 - Способ очистки нейротоксина клостридий - Google Patents

Способ очистки нейротоксина клостридий

Info

Publication number
EA201890851A1
EA201890851A1 EA201890851A EA201890851A EA201890851A1 EA 201890851 A1 EA201890851 A1 EA 201890851A1 EA 201890851 A EA201890851 A EA 201890851A EA 201890851 A EA201890851 A EA 201890851A EA 201890851 A1 EA201890851 A1 EA 201890851A1
Authority
EA
Eurasian Patent Office
Prior art keywords
neurotoxin
contacting
present
clostridial
clostride
Prior art date
Application number
EA201890851A
Other languages
English (en)
Other versions
EA036610B1 (ru
Inventor
Стефен Гэвин Хэкетт
Шилпа Палан
Дина Брэди Андерсон
Original Assignee
Ипсен Биофарм Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ипсен Биофарм Лимитед filed Critical Ипсен Биофарм Лимитед
Publication of EA201890851A1 publication Critical patent/EA201890851A1/ru
Publication of EA036610B1 publication Critical patent/EA036610B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ очистки нейротоксина клостридий, включающий контактирование катионообменной смолы с композицией, содержащей нейротоксин клостридий, где стадию контактирования проводят по меньшей мере при pH 7,3 и где указанную стадию контактирования катионообменной смолы с композицией, содержащей указанный нейротоксин клостридий, проводят до превращения нейротоксина клостридий из одноцепочечной формы в двухцепочечную форму. Настоящее изобретение также относится к применению буфера, имеющего значение pH, которое составляет -1 или выше, чем вычисленная pI нейротоксина клостридий; к промежуточным продуктам очистки и нейротоксинам клостридий, получаемым в соответствии с настоящим изобретением, где нейротоксин клостридий присутствует в одноцепочечной форме.
EA201890851A 2015-10-02 2016-09-27 Способ очистки нейротоксина клостридий EA036610B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1517450.1A GB201517450D0 (en) 2015-10-02 2015-10-02 Method
PCT/EP2016/072986 WO2017055274A1 (en) 2015-10-02 2016-09-27 Method for purifying clostridial neurotoxin

Publications (2)

Publication Number Publication Date
EA201890851A1 true EA201890851A1 (ru) 2018-08-31
EA036610B1 EA036610B1 (ru) 2020-11-30

Family

ID=54606010

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890851A EA036610B1 (ru) 2015-10-02 2016-09-27 Способ очистки нейротоксина клостридий

Country Status (20)

Country Link
US (1) US11066451B2 (ru)
EP (2) EP3356391B1 (ru)
JP (1) JP2018537412A (ru)
KR (1) KR20180080205A (ru)
CN (1) CN108137657A (ru)
AU (1) AU2016330322A1 (ru)
BR (1) BR112018006300A2 (ru)
CA (1) CA2996695A1 (ru)
DK (1) DK3356391T3 (ru)
EA (1) EA036610B1 (ru)
ES (1) ES2769775T3 (ru)
GB (1) GB201517450D0 (ru)
HK (2) HK1255471A1 (ru)
HU (1) HUE047489T2 (ru)
MX (2) MX2018003644A (ru)
PL (1) PL3356391T3 (ru)
PT (1) PT3356391T (ru)
SG (1) SG10202001084VA (ru)
WO (1) WO2017055274A1 (ru)
ZA (1) ZA201801755B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795197C1 (ru) * 2019-04-15 2023-05-02 Джетема Ко., Лтд. Способ очистки ботулинического токсина

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2490986T (pt) * 2009-10-21 2018-11-13 Revance Therapeutics Inc Métodos e sistemas para purificar neurotoxina botulínica não complexada
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201914034D0 (en) * 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
AU2021238924A1 (en) 2020-03-16 2022-08-25 Ipsen Biopharm Limited Modified botulinum neurotoxin for treating limb spasticity
CN113832069B (zh) * 2020-11-30 2024-01-30 河南农业大学 丁酸梭菌及其应用
KR20230163470A (ko) * 2021-03-30 2023-11-30 입센 바이오팜 리미티드 통증 ＆ 염증성 장애의 치료
WO2023041934A1 (en) 2021-09-16 2023-03-23 Ipsen Biopharm Limited Modified bont/a for use in the treatment of cervical dystonia
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
CA3228712A1 (en) 2021-09-23 2023-03-30 Nicolae GRIGORE Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
KR20240051355A (ko) * 2022-10-12 2024-04-22 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
EP1099445A3 (en) 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5714469A (en) 1994-09-01 1998-02-03 Smithkline Beecham Corporation Method of treating sepsis
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DE59903410D1 (de) 1998-05-13 2002-12-19 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
CA2335105C (en) 1998-07-22 2010-05-11 Osprey Pharmaceuticals Limited Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
EP1700918B1 (en) 1999-08-25 2014-01-15 Allergan, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
ITBO20010426A1 (it) * 2001-07-06 2003-01-06 Alfa Wassermann Spa Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
AU2003287155A1 (en) 2002-10-15 2004-05-04 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
CN1616489A (zh) * 2004-09-30 2005-05-18 中国科学技术大学 纯化重组人白细胞介素12的方法
EP1830872B1 (en) 2004-12-01 2010-11-17 Health Protection Agency Fusion proteins
CN1946738A (zh) 2005-03-03 2007-04-11 阿勒根公司 用于纯化肉毒毒素的不含动物产物的系统和方法
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2341892T5 (es) 2005-09-19 2019-03-27 Allergan Inc Toxina clostridial activable por toxinas clostridiales
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
RU2571212C2 (ru) * 2009-02-19 2015-12-20 Мерц Фарма Гмбх Унд Ко. Кгаа Средства и способы получения высокоочищенного нейротоксина
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
CN101497909B (zh) * 2009-03-05 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 制备抗a型肉毒毒素免疫球蛋白抗体的方法
JP5764550B2 (ja) 2009-04-14 2015-08-19 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド 遺伝子工学的ボツリヌス神経毒
US8440204B2 (en) 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
PT2490986T (pt) 2009-10-21 2018-11-13 Revance Therapeutics Inc Métodos e sistemas para purificar neurotoxina botulínica não complexada
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
WO2013091895A1 (en) * 2011-12-23 2013-06-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of di-chain proteins for use in humans
BR112015003591B1 (pt) 2012-11-21 2022-02-01 Ipsen Bioinnovation Limited Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US10647750B2 (en) * 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795197C1 (ru) * 2019-04-15 2023-05-02 Джетема Ко., Лтд. Способ очистки ботулинического токсина

Also Published As

Publication number Publication date
AU2016330322A1 (en) 2018-04-26
CA2996695A1 (en) 2017-04-06
EP3650462A1 (en) 2020-05-13
EP3356391A1 (en) 2018-08-08
HUE047489T2 (hu) 2020-04-28
ZA201801755B (en) 2019-01-30
ES2769775T3 (es) 2020-06-29
HK1257762A1 (zh) 2019-10-25
GB201517450D0 (en) 2015-11-18
EA036610B1 (ru) 2020-11-30
JP2018537412A (ja) 2018-12-20
HK1255471A1 (zh) 2019-08-16
CN108137657A (zh) 2018-06-08
WO2017055274A1 (en) 2017-04-06
MX2020011816A (es) 2021-01-15
DK3356391T3 (da) 2020-02-03
US20190100564A1 (en) 2019-04-04
BR112018006300A2 (pt) 2018-10-16
EP3356391B1 (en) 2019-11-06
KR20180080205A (ko) 2018-07-11
PT3356391T (pt) 2020-02-19
PL3356391T3 (pl) 2020-07-27
SG10202001084VA (en) 2020-03-30
US11066451B2 (en) 2021-07-20
MX2018003644A (es) 2018-04-30

Similar Documents

Publication Publication Date Title
EA201890851A1 (ru) Способ очистки нейротоксина клостридий
MX2023010757A (es) Variantes de proteasa y sus usos.
EA201990651A1 (ru) Распределяемые системы для эффективного продуцирования и применения композиций на основе микроорганизмов
MX2018004683A (es) Composicion detergente que comprende variantes de amilasa y proteasa.
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EP4234693A3 (en) Bacillus gibsonii-clade serine proteases
EA202091296A1 (ru) Расщепляющие ненейронный snare ботулинические нейротоксины
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
PE20171382A1 (es) ARNi VARIANTE
NZ728437A (en) Methods for increasing cas9-mediated engineering efficiency
EP4219704A3 (en) Aprl-clade protease variants and uses thereof
EA201490052A1 (ru) Соединения, ингибирующие металлоферменты
EA201490038A1 (ru) Соединения, ингибирующие металлоферменты
EA201890710A1 (ru) Способ очистки гидролизата биомассы
MX2017015668A (es) Microorganismos recombinante para la produccion mejorada de quimicos finos.
PH12017502240A1 (en) Recombinant microorganism for improved production of alanine
EA201490299A1 (ru) Способ удаления примесей из конденсата топочного газа
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
EA201792538A1 (ru) Способ биологического получения метакриловой кислоты
EA201700217A1 (ru) Способ очистки для выделения и коммерческого производства рекомбинантной tnk-tpa (тенектеплазы)
AR102318A1 (es) Composiciones que comprenden polipéptidos que tienen actividad fosfolipasa c y sus usos
FR3013219B1 (fr) Procede d'obtention d'extraits d'algues marines
AR100607A1 (es) Un método para la modificación de una lipasa
UA114997C2 (uk) Рекомбінантний мікроорганізм з роду escherichia, що виробляє l-амінокислоту, та спосіб одержання l-амінокислоти
MY193588A (en) Improved microorganisms for succinic acid production